Background: Although resistance associated amino acid variants (RAVs) declined to below detectable levels by Sanger sequencing methodology in the majority of patients enrolled in the long-term follow-up study P05063, ~30% of these patients had viruses with RAVs detected by population sequencing >2 years after cessation of boceprevir dosing. In order to further investigate the persistence of RAVs and to assess the limits of detection of the population sequencing technique employed in boceprevir clinical trials, RAVs were quantified using a sensitive clonal quantitative nucleotide sequencing method. Paired samples from 20 patients at baseline (prior to boceprevir treatment) and >2 years after virologic failure with RAVs in a boceprevir clinical study were evaluated for RAVs using PrimerID/454-sequence analysis. Methodology: Viral RNA was isolated from blood plasma and cDNA generated by reverse transcription using a PrimerID tag. Approximately 20,000 copies of viral RNA from each sample were present in the cDNA synthesis reaction. The gene was then amplified by nested PCR. Once amplified, 3 to 4 tagged samples were combined and sequenced on the 454 GS FLX+ Platform with XLR70 Titanium Chemistry as per manufacturer’s instructions with ~300,000 beads loaded per region. Results: The PrimerID 454 sequencing method identified RAVs at baseline in 6/20 patients whereas two of these patients had RAVs detected by population sequencing. The additional baseline RAVs identified by PrimerID were detected at ≤2.6% of the total circulating virus population. Of the 20 patients that experienced virologic failure with RAVs detected by population sequencing, 9/20 no longer had RAVs detected by 454 technology after 1-2 years of follow-up. Of the 11/20 patients with detectable RAVs, the RAVs had declined to ≤4.3% of the total circulating viral population in all but three patients. In these three patients with RAVs detected at high levels, the RAVs were also detected by population sequencing. Conclusions: The 454-Primer ID technology employed in this study detected RAVs present at low levels (>10%) in the circulating population. The clinical implications of the additional low level RAVs detected by PrimerID sequencing at baseline and during long term follow-up, which in the majority of cases were detected at levels below 1% of the total circulating virus population, are not understood.